D.E. Shaw & Co
AGL icon

D.E. Shaw & Co’s Agilon Health AGL Stock Holding History

D.E. Shaw & Co’s Portfolio AGL Stock Details AGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,800
Closed -$133K – 4217
2024
Q4 		$133K Sell
2,800
-484
-15% -$29.3K ﹤0.01% 4141
2024
Q3 		$323K Buy
3,284
+484
+17% +$62.5K ﹤0.01% 3939
2024
Q2 		$458K Buy
+2,800
New +$399K ﹤0.01% 3674

Other funds holding AGL

CDR
Clayton Dubilier & Rice New York $536M AUM 0.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NPCM
North Peak Capital Management New York $601M AUM 0.2% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's AGL Position: Q1 2026 in Review

D.E. Shaw & Co reduced its Agilon Health (AGL) stake by 8.6% in Q1 2026, selling an estimated $1.14M and leaving 742,218 shares worth $5.87M. The position accounts for ﹤0.01% of the portfolio, ranked #2062.

D.E. Shaw & Co first reported a position in AGL in Q2 2021 and has held it in 12 quarters since. The position peaked at $14M in Q4 2025. 97 funds tracked by Wall St. Rank hold AGL as of Q1 2026.

  • D.E. Shaw & Co held 742,218 shares of Agilon Health worth $5.87M as of Q1 2026.
  • D.E. Shaw & Co sold 70,235 Agilon Health shares in Q1 2026, an estimated $1.14M.
  • Agilon Health made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q1 2026, its #2062 holding.
  • D.E. Shaw & Co first reported a position in Agilon Health in Q2 2021 and has held it in 12 quarters since.
  • D.E. Shaw & Co's Agilon Health position peaked at $14M in Q4 2025.
  • 97 funds tracked by Wall St. Rank held Agilon Health as of Q1 2026.

Based on D.E. Shaw & Co's 13F filing for Q1 2026, filed 15 May 2026.